Form 4: Tango Therapeutics Executive Adam Crystal Reports Stock and Option Awards

Adam Crystal, a key executive at Tango Therapeutics, reports the acquisition of restricted stock units and stock options, signaling potential future ownership in the company.

Summary

• Adam Crystal, President of Research & Development at Tango Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 3, 2025, Crystal acquired 53,015 restricted stock units (RSUs) at a price of $0.
• These RSUs vest over a three-year period: 33% on February 2, 2026, 33% on February 1, 2027, and 34% on February 14, 2028, contingent upon continued service.
• Crystal also acquired options to purchase 318,090 shares of common stock at an exercise price of $2.91.
• These options vest over a four-year period, with 25% vesting on January 1, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter.
• Following these transactions, Crystal directly owns 172,493 shares of common stock and options for 318,090 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects standard executive compensation practices that align management interests with shareholder value. The vesting schedules suggest a long-term commitment.

Positives

• The acquisition of RSUs and stock options by a key executive like Adam Crystal can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the RSUs and stock options incentivize long-term commitment from Crystal.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a focus on long-term value creation and retention of key personnel.

Industry Context

Stock and option awards are common compensation tools in the biotechnology industry to attract and retain talent, aligning executive interests with shareholder value.

Comparison to Industry Standards

• Equity compensation packages, including stock options and RSUs, are standard practice in the biotech industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant similar awards to their executives.
• The vesting schedules described are typical, with multi-year vesting periods designed to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the equity awards as a positive sign, aligning executive interests with long-term company performance.
• Employees may see the awards as a sign of confidence in the company's future, potentially boosting morale.

Key Dates

Keywords

Form 4, Tango Therapeutics, Adam Crystal, Stock Options, Restricted Stock Units, Beneficial Ownership, Vesting